Abstract
G protein coupled receptors (GPCRs) are extremely important drug targets and the β-arrestin intracellular scaffolding and adaptor proteins regulate major aspects of their pharmacology. β-arrestin binding to activated, GPCR kinase (GRK)-phosphorylated receptors has the capacity to terminate G protein coupling, internalize the receptors into clathrincoated vesicles and establish a secondary signaling complex independent of G protein signaling. These events appear to be differentially regulated by GRK phosphorylation, ubiquitination and potentially β-arrestin oligomerization, which are likely to be highly receptor and cell-type dependent. The role of β-arrestins in switching from G-protein dependent to independent signaling places them in a pivotal position to dictate the downstream effects of ligand binding. Consequently, we must appreciate the functioning of these molecules as we strive to discover and optimize new GPCR drug therapies for endocrine, metabolic and immune disorders.
Keywords: G protein coupled receptor, GPCR, β-arrestin, endocytosis, internalisation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: G Protein Coupled Receptors as Drug Targets: The Role of β-Arrestins
Volume: 8 Issue: 1
Author(s): Jasmin R. Dromey and Kevin D.G. Pfleger
Affiliation:
Keywords: G protein coupled receptor, GPCR, β-arrestin, endocytosis, internalisation
Abstract: G protein coupled receptors (GPCRs) are extremely important drug targets and the β-arrestin intracellular scaffolding and adaptor proteins regulate major aspects of their pharmacology. β-arrestin binding to activated, GPCR kinase (GRK)-phosphorylated receptors has the capacity to terminate G protein coupling, internalize the receptors into clathrincoated vesicles and establish a secondary signaling complex independent of G protein signaling. These events appear to be differentially regulated by GRK phosphorylation, ubiquitination and potentially β-arrestin oligomerization, which are likely to be highly receptor and cell-type dependent. The role of β-arrestins in switching from G-protein dependent to independent signaling places them in a pivotal position to dictate the downstream effects of ligand binding. Consequently, we must appreciate the functioning of these molecules as we strive to discover and optimize new GPCR drug therapies for endocrine, metabolic and immune disorders.
Export Options
About this article
Cite this article as:
Dromey R. Jasmin and Pfleger D.G. Kevin, G Protein Coupled Receptors as Drug Targets: The Role of β-Arrestins, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/187153008783928352
DOI https://dx.doi.org/10.2174/187153008783928352 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
Call for Papers in Thematic Issues
Chronic inflammation and Disorders/Cancers
Chronic inflammation is fundamental cause of variety of disorders. Many lifestyle-related diseases including metabolic syndrome, obesity, impairment of immune responses, sepsis, mental illness, and other disorders are caused by chronic inflammation. Prevention of chronic inflammation is related to antiaging effects of our body. Proinflammatory cytokines such as TNF-α is associated ...read more
Immune defense of the blood-tissue barriers which are related to drugs, metabolic and hormones
We have already known that testis is an immune privilege area for the maintenance of spermatogenesis against to any pathogen from the interstitial area. With the BTB integrity there is a qualified selection for the mature sperm until the lumen migration which is sperm release progress. Spermiogenesis help for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
iTRAQ-Based Quantitative Proteomics Analysis Reveals the Invasion
Mechanism of <i>Spiroplasma eriocheiris</i> in 3T6 Cells
Current Proteomics MicroRNA Regulatory Network in Human Colorectal Cancer
Mini-Reviews in Medicinal Chemistry High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection <i>via</i> Microarray Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Biological Markers in Older People at Risk of Mobility Limitations
Current Pharmaceutical Design Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Stem Cell-Based Approaches for Intervertebral Disc Regeneration
Current Stem Cell Research & Therapy ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target
Current Pharmaceutical Design Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Cellular and Molecular Regulation of Inflammatory Pain, Nociception and Hyperalgesia - The Role of the Transcription Factor NF-κB as the Lynchpin Nocisensor: Hyperalgesic or Analgesic Effect?
Current Immunology Reviews (Discontinued) Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Anticancer Properties of Essential Oils: An Overview
Current Cancer Drug Targets The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry Recent Advances in Optimal Adjunctive Antithrombotic Therapy in STEMI Patients Undergoing Primary Angioplasty: An Overview
Current Vascular Pharmacology COX-2 Signaling and Cancer: New Players in Old Arena
Current Drug Targets The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1)
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Targeting in Inherited Arrhythmia Syndromes
Current Medicinal Chemistry A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry